+1 (704) 266-3234

Global Biosimilar Drug Market Growth 2020-2025

Published on: Jul 2020 | From USD $3660 | Published By: LP INFORMATION INC | Number Of Pages: 136

COVID-19, the disease it causes, surfaced in late 2019, and now had become a full-blown crisis worldwide. Over fifty key countries had declared a national emergency to combat coronavirus. With cases spreading, and the epicentre of the outbreak shifting to Europe, North America, India and Latin America, life in these regions has been upended the way it had been in Asia earlier in the developing crisis. As the coronavirus pandemic has worsened, the entertainment industry has been upended along with most every other facet of life. As experts work toward a better understanding, the world shudders in fear of the unknown, a worry that has rocked global financial markets, leading to daily volatility in the U.S. stock markets.

According to this latest study, the 2020 growth of Biosimilar Drug will have significant change from previous year. By the most conservative estimates of global Biosimilar Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. We give this scenario a XX% probability, where under the scenario the supply chain will start to recover and quarantines and travel bans will ease, over the Q2. Longer-term, the effect of COVID-19 will be felt throughout the year with some degree of harm done by the virus. Over the next five years the Biosimilar Drug market will register a XX% CAGR in terms of revenue, the global market size will reach US$ XX million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Drug market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Biosimilar Drug, covering the supply chain analysis, impact assessment to the Biosimilar Drug market size growth rate in several scenarios, and the measures to be undertaken by Biosimilar Drug companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Injection
Tablets
Other Types

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Ankylosing Spondylitis
Tumor
Rheumatoid Arthrtis
Cardiovascular
Other Application

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Amgen
Eli Lilly
CP Guojian Pharma
Biotech Pharma
Novartis
...

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Biosimilar Drug consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Biosimilar Drug market by identifying its various subsegments.
Focuses on the key global Biosimilar Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Biosimilar Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Biosimilar Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 What is the Impact of Covid-19 Outbreak On the Biosimilar Drug?
1.8.1 Optimistic Scenario: COVID-19 Is Contained by May or June, with Normalcy Returning to Global Operations Through the End of Q2.
1.8.2 Conservative Scenario: COVID-19 Remains Prevalent, with Continued Impacts Lasting Into Q4.
1.8.3 Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Biosimilar Drug Market Size in 2020, by Scenario
1.8.4 Corporate Strategy the Manufacturers Should Be Thinking About Right Now

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biosimilar Drug Consumption 2015-2025
2.1.2 Biosimilar Drug Consumption CAGR by Region
2.2 Biosimilar Drug Segment by Type
2.2.1 Injection
2.2.2 Tablets
2.2.3 Other Types
2.3 Biosimilar Drug Consumption by Type
2.3.1 Global Biosimilar Drug Consumption Market Share by Type (2015-2020)
2.3.2 Global Biosimilar Drug Revenue and Market Share by Type (2015-2020)
2.3.3 Global Biosimilar Drug Sale Price by Type (2015-2020)
2.4 Biosimilar Drug Segment by Application
2.4.1 Ankylosing Spondylitis
2.4.2 Tumor
2.4.3 Rheumatoid Arthrtis
2.4.4 Cardiovascular
2.4.5 Other Application
2.5 Biosimilar Drug Consumption by Application
2.5.1 Global Biosimilar Drug Consumption Market Share by Type (2015-2020)
2.5.2 Global Biosimilar Drug Value and Market Share by Type (2015-2020)
2.5.3 Global Biosimilar Drug Sale Price by Type (2015-2020)

3 Global Biosimilar Drug by Company
3.1 Global Biosimilar Drug Sales Market Share by Company
3.1.1 Global Biosimilar Drug Sales by Company (2018-2020)
3.1.2 Global Biosimilar Drug Sales Market Share by Company (2018-2020)
3.2 Global Biosimilar Drug Revenue Market Share by Company
3.2.1 Global Biosimilar Drug Revenue by Company (2018-2020)
3.2.2 Global Biosimilar Drug Revenue Market Share by Company (2018-2020)
3.3 Global Biosimilar Drug Sale Price by Company
3.4 Global Biosimilar Drug Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Biosimilar Drug Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Biosimilar Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Biosimilar Drug by Regions
4.1 Biosimilar Drug by Regions
4.2 Americas Biosimilar Drug Consumption Growth
4.3 APAC Biosimilar Drug Consumption Growth
4.4 Europe Biosimilar Drug Consumption Growth
4.5 Middle East & Africa Biosimilar Drug Consumption Growth

5 Americas
5.1 Americas Biosimilar Drug Consumption by Countries
5.1.1 Americas Biosimilar Drug Consumption by Countries (2015-2020)
5.1.2 Americas Biosimilar Drug Value by Countries (2015-2020)
5.2 Americas Biosimilar Drug Consumption by Type
5.3 Americas Biosimilar Drug Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Biosimilar Drug Consumption by Regions
6.1.1 APAC Biosimilar Drug Consumption by Regions (2015-2020)
6.1.2 APAC Biosimilar Drug Value by Regions (2015-2020)
6.2 APAC Biosimilar Drug Consumption by Type
6.3 APAC Biosimilar Drug Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Biosimilar Drug by Countries
7.1.1 Europe Biosimilar Drug Consumption by Countries (2015-2020)
7.1.2 Europe Biosimilar Drug Value by Countries (2015-2020)
7.2 Europe Biosimilar Drug Consumption by Type
7.3 Europe Biosimilar Drug Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Biosimilar Drug by Countries
8.1.1 Middle East & Africa Biosimilar Drug Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Biosimilar Drug Value by Countries (2015-2020)
8.2 Middle East & Africa Biosimilar Drug Consumption by Type
8.3 Middle East & Africa Biosimilar Drug Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Biosimilar Drug Distributors
10.3 Biosimilar Drug Customer

11 Global Biosimilar Drug Market Forecast
11.1 Global Biosimilar Drug Consumption Forecast (2021-2025)
11.2 Global Biosimilar Drug Forecast by Regions
11.2.1 Global Biosimilar Drug Forecast by Regions (2021-2025)
11.2.2 Global Biosimilar Drug Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Biosimilar Drug Forecast by Type
11.8 Global Biosimilar Drug Forecast by Application

12 Key Players Analysis
12.1 Amgen
12.1.1 Company Information
12.1.2 Biosimilar Drug Product Offered
12.1.3 Amgen Biosimilar Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Amgen Latest Developments
12.2 Eli Lilly
12.2.1 Company Information
12.2.2 Biosimilar Drug Product Offered
12.2.3 Eli Lilly Biosimilar Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Eli Lilly Latest Developments
12.3 CP Guojian Pharma
12.3.1 Company Information
12.3.2 Biosimilar Drug Product Offered
12.3.3 CP Guojian Pharma Biosimilar Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 CP Guojian Pharma Latest Developments
12.4 Biotech Pharma
12.4.1 Company Information
12.4.2 Biosimilar Drug Product Offered
12.4.3 Biotech Pharma Biosimilar Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Biotech Pharma Latest Developments
12.5 Novartis
12.5.1 Company Information
12.5.2 Biosimilar Drug Product Offered
12.5.3 Novartis Biosimilar Drug Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Novartis Latest Developments
...

13 Research Findings and Conclusion

List of Tables
Table 1. Estimated Impact of the Coronavirus (COVID-19) Epidemic on the Global Biosimilar Drug Market Size in 2020, by Scenario
Table 2. COVID-19: Measures to be Undertaken by Biosimilar Drug Companies
Table 3. Research Methodology
Table 4. Data Source
Table 5. Biosimilar Drug Consumption CAGR by Region 2015-2025 ($ Millions)
Table 6. Major Players of Injection
Table 7. Major Players of Tablets
Table 8. Major Players of Other Types
Table 9. Global Consumption Sales by Type (2015-2020)
Table 10. Global Biosimilar Drug Consumption Market Share by Type (2015-2020)
Table 11. Global Biosimilar Drug Revenue by Type (2015-2020) ($ million)
Table 12. Global Biosimilar Drug Value Market Share by Type (2015-2020) ($ Millions)
Table 13. Global Biosimilar Drug Sale Price by Type (2015-2020)
Table 14. Global Consumption Sales by Application (2015-2020)
Table 15. Global Biosimilar Drug Consumption Market Share by Application (2015-2020)
Table 16. Global Biosimilar Drug Value by Application (2015-2020)
Table 17. Global Biosimilar Drug Value Market Share by Application (2015-2020)
Table 18. Global Biosimilar Drug Sale Price by Application (2015-2020)
Table 19. Global Biosimilar Drug Sales by Company (2017-2019) (K Dose)
Table 20. Global Biosimilar Drug Sales Market Share by Company (2017-2019)
Table 21. Global Biosimilar Drug Revenue by Company (2017-2019) ($ Millions)
Table 22. Global Biosimilar Drug Revenue Market Share by Company (2017-2019)
Table 23. Global Biosimilar Drug Sale Price by Company (2017-2019)
Table 24. Global Biosimilar Drug Manufacturing Base Distribution and Sales Area by Manufacturers
Table 25. Players Biosimilar Drug Products Offered
Table 26. Biosimilar Drug Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 27. Global Biosimilar Drug Consumption by Regions 2015-2020 (K Dose)
Table 28. Global Biosimilar Drug Consumption Market Share by Regions 2015-2020
Table 29. Global Biosimilar Drug Value by Regions 2015-2020 ($ Millions)
Table 30. Global Biosimilar Drug Value Market Share by Regions 2015-2020
Table 31. Americas Biosimilar Drug Consumption by Countries (2015-2020) (K Dose)
Table 32. Americas Biosimilar Drug Consumption Market Share by Countries (2015-2020)
Table 33. Americas Biosimilar Drug Value by Countries (2015-2020) ($ Millions)
Table 34. Americas Biosimilar Drug Value Market Share by Countries (2015-2020)
Table 35. Americas Biosimilar Drug Consumption by Type (2015-2020) (K Dose)
Table 36. Americas Biosimilar Drug Consumption Market Share by Type (2015-2020)
Table 37. Americas Biosimilar Drug Consumption by Application (2015-2020) (K Dose)
Table 38. Americas Biosimilar Drug Consumption Market Share by Application (2015-2020)
Table 39. APAC Biosimilar Drug Consumption by Countries (2015-2020) (K Dose)
Table 40. APAC Biosimilar Drug Consumption Market Share by Countries (2015-2020)
Table 41. APAC Biosimilar Drug Value by Regions (2015-2020) ($ Millions)
Table 42. APAC Biosimilar Drug Value Market Share by Regions (2015-2020)
Table 43. APAC Biosimilar Drug Consumption by Type (2015-2020) (K Dose)
Table 44. APAC Biosimilar Drug Consumption Market Share by Type (2015-2020)
Table 45. APAC Biosimilar Drug Consumption by Application (2015-2020) (K Dose)
Table 46. APAC Biosimilar Drug Consumption Market Share by Application (2015-2020)
Table 47. Europe Biosimilar Drug Consumption by Countries (2015-2020) (K Dose)
Table 48. Europe Biosimilar Drug Consumption Market Share by Countries (2015-2020)
Table 49. Europe Biosimilar Drug Value by Countries (2015-2020) ($ Millions)
Table 50. Europe Biosimilar Drug Value Market Share by Countries (2015-2020)
Table 51. Europe Biosimilar Drug Consumption by Type (2015-2020) (K Dose)
Table 52. Europe Biosimilar Drug Consumption Market Share by Type (2015-2020)
Table 53. Europe Biosimilar Drug Consumption by Application (2015-2020) (K Dose)
Table 54. Europe Biosimilar Drug Consumption Market Share by Application (2015-2020)
Table 55. Middle East & Africa Biosimilar Drug Consumption by Countries (2015-2020) (K Dose)
Table 56. Middle East & Africa Biosimilar Drug Consumption Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Biosimilar Drug Value by Countries (2015-2020) ($ Millions)
Table 58. Middle East & Africa Biosimilar Drug Value Market Share by Countries (2015-2020)
Table 59. Middle East & Africa Biosimilar Drug Consumption by Type (2015-2020) (K Dose)
Table 60. Middle East & Africa Biosimilar Drug Consumption Market Share by Type (2015-2020)
Table 61. Middle East & Africa Biosimilar Drug Consumption by Application (2015-2020) (K Dose)
Table 62. Middle East & Africa Biosimilar Drug Consumption Market Share by Application (2015-2020)
Table 63. Biosimilar Drug Distributors List
Table 64. Biosimilar Drug Customer List
Table 65. Global Biosimilar Drug Consumption Forecast by Countries (2021-2025) (K Dose)
Table 66. Global Biosimilar Drug Consumption Market Forecast by Regions
Table 67. Global Biosimilar Drug Value Forecast by Countries (2021-2025) ($ Millions)
Table 68. Global Biosimilar Drug Value Market Share Forecast by Regions
Table 69. Global Biosimilar Drug Consumption Forecast by Type (2021-2025) (K Dose)
Table 70. Global Biosimilar Drug Consumption Market Share Forecast by Type (2021-2025)
Table 71. Global Biosimilar Drug Value Forecast by Type (2021-2025) ($ Millions)
Table 72. Global Biosimilar Drug Value Market Share Forecast by Type (2021-2025)
Table 73. Global Biosimilar Drug Consumption Forecast by Application (2021-2025) (K Dose)
Table 74. Global Biosimilar Drug Consumption Market Share Forecast by Application (2021-2025)
Table 75. Global Biosimilar Drug Value Forecast by Application (2021-2025) ($ Millions)
Table 76. Global Biosimilar Drug Value Market Share Forecast by Application (2021-2025)
Table 77. Amgen Product Offered
Table 78. Amgen Biosimilar Drug Sales (K Dose), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 79. Amgen Main Business
Table 80. Amgen Latest Developments
Table 81. Amgen Basic Information, Company Total Revenue (in $ million), Biosimilar Drug Manufacturing Base, Sales Area and Its Competitors
Table 82. Eli Lilly Product Offered
Table 83. Eli Lilly Biosimilar Drug Sales (K Dose), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 84. Eli Lilly Main Business
Table 85. Eli Lilly Latest Developments
Table 86. Eli Lilly Basic Information, Company Total Revenue (in $ million), Biosimilar Drug Manufacturing Base, Sales Area and Its Competitors
Table 87. CP Guojian Pharma Product Offered
Table 88. CP Guojian Pharma Biosimilar Drug Sales (K Dose), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 89. CP Guojian Pharma Main Business
Table 90. CP Guojian Pharma Latest Developments
Table 91. CP Guojian Pharma Basic Information, Company Total Revenue (in $ million), Biosimilar Drug Manufacturing Base, Sales Area and Its Competitors
Table 92. Biotech Pharma Product Offered
Table 93. Biotech Pharma Biosimilar Drug Sales (K Dose), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 94. Biotech Pharma Main Business
Table 95. Biotech Pharma Latest Developments
Table 96. Biotech Pharma Basic Information, Company Total Revenue (in $ million), Biosimilar Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis Product Offered
Table 98. Novartis Biosimilar Drug Sales (K Dose), Revenue ($ Million), Price (USD/Dose) and Gross Margin (2018-2020E)
Table 99. Novartis Main Business
Table 100. Novartis Latest Developments
Table 101. Novartis Basic Information, Company Total Revenue (in $ million), Biosimilar Drug Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Biosimilar Drug
Figure 2. Biosimilar Drug Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Biosimilar Drug Consumption Growth Rate 2015-2025 (K Dose)
Figure 5. Global Biosimilar Drug Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Injection
Figure 7. Product Picture of Tablets
Figure 8. Product Picture of Other Types
Figure 9. Global Biosimilar Drug Consumption Market Share by Type (2015-2020)
Figure 10. Global Biosimilar Drug Value Market Share by Type (2015-2020)
Figure 11. Biosimilar Drug Consumed in Ankylosing Spondylitis
Figure 12. Global Biosimilar Drug Market: Ankylosing Spondylitis (2015-2020) (K Dose)
Figure 13. Global Biosimilar Drug Market: Ankylosing Spondylitis (2015-2020) ($ Millions)
Figure 14. Biosimilar Drug Consumed in Tumor
Figure 15. Global Biosimilar Drug Market: Tumor (2015-2020) (K Dose)
Figure 16. Global Biosimilar Drug Market: Tumor (2015-2020) ($ Millions)
Figure 17. Biosimilar Drug Consumed in Rheumatoid Arthrtis
Figure 18. Global Biosimilar Drug Market: Rheumatoid Arthrtis (2015-2020) (K Dose)
Figure 19. Global Biosimilar Drug Market: Rheumatoid Arthrtis (2015-2020) ($ Millions)
Figure 20. Biosimilar Drug Consumed in Cardiovascular
Figure 21. Global Biosimilar Drug Market: Cardiovascular (2015-2020) (K Dose)
Figure 22. Global Biosimilar Drug Market: Cardiovascular (2015-2020) ($ Millions)
Figure 23. Biosimilar Drug Consumed in Other Application
Figure 24. Global Biosimilar Drug Market: Other Application (2015-2020) (K Dose)
Figure 25. Global Biosimilar Drug Market: Other Application (2015-2020) ($ Millions)
Figure 26. Global Biosimilar Drug Consumption Market Share by Application (2015-2020)
Figure 27. Global Biosimilar Drug Value Market Share by Application (2015-2020)
Figure 28. Global Biosimilar Drug Sales Market Share by Company in 2017
Figure 29. Global Biosimilar Drug Sales Market Share by Company in 2019
Figure 30. Global Biosimilar Drug Revenue Market Share by Company in 2017
Figure 31. Global Biosimilar Drug Revenue Market Share by Company in 2019
Figure 32. Global Biosimilar Drug Sale Price by Company in 2019
Figure 33. Global Biosimilar Drug Consumption Market Share by Regions 2015-2020
Figure 34. Global Biosimilar Drug Value Market Share by Regions 2015-2020
Figure 35. Americas Biosimilar Drug Consumption 2015-2020 (K Dose)
Figure 36. Americas Biosimilar Drug Value 2015-2020 ($ Millions)
Figure 37. APAC Biosimilar Drug Consumption 2015-2020 (K Dose)
Figure 38. APAC Biosimilar Drug Value 2015-2020 ($ Millions)
Figure 39. Europe Biosimilar Drug Consumption 2015-2020 (K Dose)
Figure 40. Europe Biosimilar Drug Value 2015-2020 ($ Millions)
Figure 41. Middle East & Africa Biosimilar Drug Consumption 2015-2020 (K Dose)
Figure 42. Middle East & Africa Biosimilar Drug Value 2015-2020 ($ Millions)
Figure 43. Americas Biosimilar Drug Consumption Market Share by Countries in 2019
Figure 44. Americas Biosimilar Drug Value Market Share by Countries in 2019
Figure 45. Americas Biosimilar Drug Consumption Market Share by Type in 2019
Figure 46. Americas Biosimilar Drug Consumption Market Share by Application in 2019
Figure 47. United States Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 48. United States Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 49. Canada Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 50. Canada Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 51. Mexico Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 52. Mexico Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 53. APAC Biosimilar Drug Consumption Market Share by Countries in 2019
Figure 54. APAC Biosimilar Drug Value Market Share by Regions in 2019
Figure 55. APAC Biosimilar Drug Consumption Market Share by Type in 2019
Figure 56. APAC Biosimilar Drug Consumption Market Share by Application in 2019
Figure 57. China Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 58. China Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 59. Japan Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 60. Japan Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 61. Korea Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 62. Korea Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 63. Southeast Asia Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 64. Southeast Asia Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 65. India Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 66. India Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 67. Australia Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 68. Australia Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 69. Europe Biosimilar Drug Consumption Market Share by Countries in 2019
Figure 70. Europe Biosimilar Drug Value Market Share by Countries in 2019
Figure 71. Europe Biosimilar Drug Consumption Market Share by Type in 2019
Figure 72. Europe Biosimilar Drug Consumption Market Share by Application in 2019
Figure 73. Germany Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 74. Germany Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 75. France Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 76. France Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 77. UK Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 78. UK Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 79. Italy Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 80. Italy Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 81. Russia Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 82. Russia Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 83. Middle East & Africa Biosimilar Drug Consumption Market Share by Countries in 2019
Figure 84. Middle East & Africa Biosimilar Drug Value Market Share by Countries in 2019
Figure 85. Middle East & Africa Biosimilar Drug Consumption Market Share by Type in 2019
Figure 86. Middle East & Africa Biosimilar Drug Consumption Market Share by Application in 2019
Figure 87. Egypt Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 88. Egypt Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 89. South Africa Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 90. South Africa Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 91. Israel Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 92. Israel Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 93. Turkey Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 94. Turkey Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 95. GCC Countries Biosimilar Drug Consumption Growth 2015-2020 (K Dose)
Figure 96. GCC Countries Biosimilar Drug Value Growth 2015-2020 ($ Millions)
Figure 97. Global Biosimilar Drug Consumption Growth Rate Forecast (2021-2025) (K Dose)
Figure 98. Global Biosimilar Drug Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 99. Americas Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 100. Americas Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 101. APAC Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 102. APAC Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 103. Europe Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 104. Europe Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 105. Middle East & Africa Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 106. Middle East & Africa Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 107. United States Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 108. United States Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 109. Canada Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 110. Canada Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 111. Mexico Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 112. Mexico Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 113. Brazil Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 114. Brazil Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 115. China Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 116. China Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 117. Japan Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 118. Japan Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 119. Korea Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 120. Korea Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 121. Southeast Asia Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 122. Southeast Asia Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 123. India Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 124. India Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 125. Australia Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 126. Australia Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 127. Germany Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 128. Germany Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 129. France Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 130. France Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 131. UK Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 132. UK Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 133. Italy Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 134. Italy Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 135. Russia Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 136. Russia Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 137. Spain Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 138. Spain Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 139. Egypt Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 140. Egypt Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 141. South Africa Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 142. South Africa Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 143. Israel Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 144. Israel Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 145. Turkey Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 146. Turkey Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 147. GCC Countries Biosimilar Drug Consumption 2021-2025 (K Dose)
Figure 148. GCC Countries Biosimilar Drug Value 2021-2025 ($ Millions)
Figure 149. Amgen Biosimilar Drug Market Share (2018-2020)
Figure 150. Eli Lilly Biosimilar Drug Market Share (2018-2020)
Figure 151. CP Guojian Pharma Biosimilar Drug Market Share (2018-2020)
Figure 152. Biotech Pharma Biosimilar Drug Market Share (2018-2020)
Figure 153. Novartis Biosimilar Drug Market Share (2018-2020)

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3660
USD $5490
USD $7320
COVID-19
Offer

WHY US?

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.